MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Podoplanin – an emerging cancer biomarker and therapeutic target

Cancer Science 2018 March 25 [Epub ahead of print] [Link]

Krishnan H et. al.

Abstract

Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts (CAFs), and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition (EMT), migration, invasion, metastasis, and inflammation. Antibodies, CAR-T cells, biologics, and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer including glioma, squamous cell carcinoma, mesothelioma, and melanoma.

Both comments and trackbacks are currently closed.